Drug Trial News

RSS

Otsuka, Lundbeck to develop investigational vaccine candidate for Alzheimer's disease

H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced that they will further expand their collaboration to include the development of Lu AF20513, an investigational vaccine candidate for Alzheimer's disease.

11 Dec 2013

Pronai Therapeutics reports positive results from PNT2258 Phase II study on lymphoma

ProNAi Therapeutics, Inc., a leader in developing nucleic acid therapeutics, presented safety and efficacy data from its ongoing Phase II study yesterday at the 55th Annual Meeting of the American Society for Hematology (ASH) in New Orleans, Louisiana.

11 Dec 2013

Pharmacyclics presents ibrutinib trial data for B-cell malignancies at ASH meeting

Pharmacyclics, Inc. today announced results of 40 clinical, non-clinical and pre-clinical presentations on ibrutinib (IMBRUVICA™) at the 55TH Annual meeting of the American Society of Hematology (ASH) held in New Orleans, Dec 7 - 10, 2013.

11 Dec 2013

Merck provides update on MK-8931 investigational oral therapy for Alzheimer’s disease

Merck, known as MSD outside the United States and Canada, today provided an update on the development program for MK-8931, a novel investigational oral β-amyloid precursor protein site-cleaving enzyme (BACE) inhibitor.

11 Dec 2013

Celgene: FIRST trial meets primary endpoint in patients newly diagnosed with multiple myeloma

Celgene today announced that data from the FIRST (Frontline Investigation of lenalidomide and dexamethasone vs. standard thalidomide) trial was presented on Sunday 8 December, during the Plenary Scientific Session at the 55th American Society Hematology annual meeting in New Orleans. FIRST (MM-020/IFM 07-01) a phase III, multi-centre study in patients newly diagnosed with multiple myeloma and ineligible for stem cell transplant, included 72 patients from the UK.

11 Dec 2013

Genzyme granted Priority Review for Cerdelga investigational oral therapy for Gaucher disease

Genzyme, a Sanofi company, announced today that the Food and Drug Administration (FDA) has granted a six-month Priority Review designation to its New Drug Application (NDA) for Cerdelga™ (eliglustat), an investigational oral therapy for adult patients with Gaucher disease type 1.

11 Dec 2013

Acetylon Pharmaceuticals presents positive preclinical data for selective HDAC1/2 inhibitors at ASH meeting

Acetylon Pharmaceuticals, Inc., the leader in the development of selective histone deacetylase (HDAC) inhibitors for enhanced therapeutic outcomes, announced that positive preclinical data for its selective HDAC1/2 inhibitors for the treatment of sickle cell disease (SCD) and β-thalassemia (bT) were presented at the 55th Annual Meeting of the American Society of Hematology (ASH) in New Orleans, LA.

11 Dec 2013

Navidea receives Fast Track designation for Lymphoseek injection

Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, announced today that the US Food and Drug Administration (FDA) has granted Fast Track designation to Lymphoseek® (technetium 99m tilmanocept) Injection for sentinel lymph node detection in patients with head and neck cancer.

11 Dec 2013

Baxter seeks FDA approval of OBI-1 for adults with acquired hemophilia A

Baxter International Inc. today announced that the company has submitted a biologics license application (BLA) to the U.S. Food and Drug Administration (FDA) for the approval of OBI-1, a recombinant antihemophilic porcine sequence factor VIII, in patients with acquired hemophilia A.

From Baxter International Inc. 11 Dec 2013

Avanir Pharmaceuticals' AVP-923 phase II trial fails to meet primary efficacy endpoint

Avanir Pharmaceuticals, Inc. today announced that PRIME, its phase II clinical trial of the investigational drug AVP-923 (dextromethorphan / quinidine) for the treatment of central neuropathic pain in patients with multiple sclerosis did not meet the primary efficacy endpoint.

10 Dec 2013

UTHealth starts clinical trial to study two forms of stem cell treatments for children with CP

A first-of-its-kind clinical trial studying two forms of stem cell treatments for children with cerebral palsy has begun at The University of Texas Health Science Center at Houston Medical School.

10 Dec 2013

Takeda presents clinical study results of oral proteasome inhibitor MLN9708 in multiple myeloma patients

Takeda Pharmaceutical Company Limited today announced final Phase 1 and preliminary Phase 2 results of a study combining oral investigational MLN9708 administered twice a week with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma.

10 Dec 2013

Acetylon announces positive preclinical data of ricolinostat (ACY-1215) in models of lymphoma

Acetylon Pharmaceuticals, Inc., the leader in the development of selective histone deacetylase (HDAC) inhibitors for enhanced therapeutic outcomes, announced that positive preclinical data of selective HDAC6 inhibitor, ricolinostat (ACY-1215), in models of lymphoma were presented today in an oral presentation by Dr. Jennifer Amengual, Assistant Professor of Medicine & Experimental Therapeutics, Columbia University Medical Center.

10 Dec 2013

European study investigates high blood pressure drug for treating Alzheimer's patients

An extensive European study is currently investigating whether a drug used to treat high blood pressure may also help patients with Alzheimer's disease. The EU is investing almost 6 million euros on the project, in which Sahlgrenska Academy and Sahlgrenska University Hospital are responsible for Sweden's contribution.

10 Dec 2013

ImmunoGen presents Phase I trial results of SAR650984 at ASH annual meeting

ImmunoGen, Inc., a biotechnology company that develops targeted, antibody-based anticancer therapeutics, today announced the first clinical findings with SAR650984 reported in an oral presentation at the ASH annual meeting. The data are from an ongoing Phase I trial assessing this CD38-targeting therapeutic antibody in patients with CD38-positive MM or other hematologic malignancy.

10 Dec 2013

CRAB CTC enrolls first patient into inaugural cancer clinical trial

Cancer Research And Biostatistics today announced enrollment of the first patient into the inaugural clinical trial sponsored by its Clinical Trials Consortium. The CRAB CTC mission is to ensure rapid clinical testing of new and innovative cancer treatments, and is focusing on lung cancer as its first target. By engaging frontline treating oncologists to push the boundaries of patient care, the aim is to improve the standard of care and extend overall survival.

9 Dec 2013

Acetylon Pharmaceuticals presents positive interim data from two ricolinostat clinical trials at ASH 2013

Acetylon Pharmaceuticals, Inc., the leader in the development of selective histone deacetylase inhibitors for enhanced therapeutic outcomes, today announced that positive interim clinical data from the two proof-of-concept clinical trials with selective HDAC6 inhibitor, ricolinostat (ACY-1215), were presented at the 55th Annual Meeting of the American Society of Hematology in New Orleans, LA.

9 Dec 2013

Arrowhead reports Phase 1 study data on ARC-520 for treatment of chronic hepatitis B infection

Arrowhead Research Corporation, a biopharmaceutical company developing targeted RNAi therapeutics, today announced that COO and Head of R&D, Bruce Given, M.D., presented data on the Phase 1 clinical study of ARC-520, the company's clinical candidate for the treatment of chronic hepatitis B infection, at the HepDART 2013 conference being held on The Big Island, Hawaii.

9 Dec 2013

NOXXON Pharma reports interim data from two phase IIa studies of anti-CXCL12/SDF-1 Spiegelmer NOX-A12

NOXXON Pharma disclosed interim data from two independent clinical phase IIa studies of the anti-CXCL12/SDF-1 Spiegelmer olaptesed pegol (NOX-A12) at the 55th annual meeting of the American Society of Hematology in New Orleans, LA, USA from 7-10 December 2013.

9 Dec 2013

Prana completes treatment phase of IMAGINE Alzheimer’s Disease clinical trial

Prana Biotechnology, a developer of best-in-class treatments for neurodegenerative disease, today announced the completion of the treatment phase of its IMAGINE Alzheimer’s Disease clinical trial.

9 Dec 2013

Drug Trial News

Otsuka, Lundbeck to develop investigational vaccine candidate for Alzheimer's disease

Pronai Therapeutics reports positive results from PNT2258 Phase II study on lymphoma

Pharmacyclics presents ibrutinib trial data for B-cell malignancies at ASH meeting

Merck provides update on MK-8931 investigational oral therapy for Alzheimer’s disease

Celgene: FIRST trial meets primary endpoint in patients newly diagnosed with multiple myeloma

Genzyme granted Priority Review for Cerdelga investigational oral therapy for Gaucher disease

Acetylon Pharmaceuticals presents positive preclinical data for selective HDAC1/2 inhibitors at ASH meeting

Navidea receives Fast Track designation for Lymphoseek injection

Baxter seeks FDA approval of OBI-1 for adults with acquired hemophilia A

Avanir Pharmaceuticals' AVP-923 phase II trial fails to meet primary efficacy endpoint

UTHealth starts clinical trial to study two forms of stem cell treatments for children with CP

Takeda presents clinical study results of oral proteasome inhibitor MLN9708 in multiple myeloma patients

Acetylon announces positive preclinical data of ricolinostat (ACY-1215) in models of lymphoma

European study investigates high blood pressure drug for treating Alzheimer's patients

ImmunoGen presents Phase I trial results of SAR650984 at ASH annual meeting

CRAB CTC enrolls first patient into inaugural cancer clinical trial

Acetylon Pharmaceuticals presents positive interim data from two ricolinostat clinical trials at ASH 2013

Arrowhead reports Phase 1 study data on ARC-520 for treatment of chronic hepatitis B infection

NOXXON Pharma reports interim data from two phase IIa studies of anti-CXCL12/SDF-1 Spiegelmer NOX-A12

Prana completes treatment phase of IMAGINE Alzheimer’s Disease clinical trial

How does norepinephrine influence anxiety-related behaviours?

Transforming Lab Workflows with Cell Culture Automation

Building Bridges to Scalable Allogeneic Cell Therapy

Latest News